Clinical Trial Update: A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating HRS-4357 versus novel androgen receptor pathway inhibitors for PSMA-positive metastatic castration-resistant prostate cancer is curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• HRS-4357

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer | Phase 3 | Status: RECRUITING